Seer, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SEER research report →
Range $4 – $4
Price Chart
About the company
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software.
- CEO
- Omid C. Farokhzad
- IPO
- 2020
- Employees
- 124
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on SEER
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $75.91M
- P/E
- -1.20
- PEG
- -0.08
- P/S
- 5.58
- P/B
- 0.36
- EV/EBITDA
- -1.19
- Div Yield
- 0.00%
- Gross Margin
- 45.70%
- Op Margin
- -477.20%
- Net Margin
- -457.86%
- ROE
- -27.03%
- ROIC
- -28.19%
Latest fiscal year · YoY change
- Revenue
- $16.12M+15.6%
- Gross Profit
- $8.01M+17.2%
- Op Income
- $-77,992,000
- Net Income
- $-73,600,000+15.0%
- EPS
- $-1.28+7.9%
- OCF Growth
- +3.6%
- FCF Growth
- +6.9%
- 52W High
- $2.38
- 52W Low
- $1.33
- 50D MA
- $1.90
- 200D MA
- $1.90
- Beta
- 1.45
- RSI (14)
- 19
- Avg Volume
- 216.07K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Seer reported a sequential revenue increase but cut full-year guidance as academic/government funding pressure and longer sales cycles delayed customer conversions, while management emphasized growing biopharma adoption, scientific validation, and a path to cash flow break-even.· November 10, 2026
- Q3 revenue was $4.0 million, up from $3.1 million in Q2, but full-year 2026 guidance was cut to $13.5 million-$14.5 million from $16 million-$18 million.
- Gross profit was about $1.9 million with a 47% gross margin, while operating expenses fell to $16.5 million, down 23% from a year ago.
- Management said established customers kept buying consumables and several new large biopharma customers adopted the Proteograph Product Suite.
- The company said customer funding constraints and uncertainty during the activist/proposal process extended sales cycles and delayed purchases.
- Seer ended the quarter with about $198 million in cash, cash equivalents, and investments, and management said existing capital should be enough to reach cash flow break-even under the current plan.
Total revenue for the third quarter of 2026 was $4.0 million, compared with $3.1 million in the second quarter. Product revenue was $2.8 million, service revenue was $1.1 million, related party revenue was $0.1 million, and other revenue was approximately $67,000. Gross profit was approximately $1.9 million, with gross margin of 47%, down 130 basis points sequentially. Operating expenses were $16.5 million versus $21.5 million in the third quarter of 2025; R&D was $6.4 million versus $10.8 million, and SG&A was $10.1 million versus $10.7 million. Net loss was $13.7 million versus $18.2 million in the third quarter of 2025. For the first nine months of 2026, net cash used in operating activities was approximately $34.5 million and free cash flow was approximately negative $34.8 million. The company ended the quarter with approximately $198 million in cash, cash equivalents, and investments. Full-year 2026 revenue guidance was lowered to $13.5 million to $14.5 million from $16 million to $18 million. Management cited longer customer purchasing timelines, academic and government funding constraints, and customer uncertainty during the activist campaign and acquisition proposals as the main reasons for the cut. They also said they expect quarterly gross margin variability but still believe long-term gross margins can be 70% to 75%, and they said current capital is sufficient to reach cash flow break-even under the operating plan.
Omid Farokhzad framed the quarter around stronger scientific validation and a broadening commercial use case for Proteograph, especially in population-scale studies and AI-related research. He said the company is seeing repeat consumable purchases, new large biopharma adopters, and a clearer message to customers after Seer decided to remain independent. His tone was confident and constructive, emphasizing that the platform’s evidence base is growing and that Seer is focused on expanding adoption, sample volume, and repeat revenue.
Charles Endweiss focused on the financial details and the revised outlook. He cited $4.0 million of revenue, $1.9 million of gross profit, a 47% gross margin, and $16.5 million of operating expenses, noting the expense base was down meaningfully from last year. He also highlighted $34.5 million of operating cash use for the first nine months, about $198 million in cash and investments, and approximately $25 million remaining under repurchase authorizations. On guidance, he said the cut to $13.5 million-$14.5 million for 2026 reflects extended sales cycles and delayed study starts, especially in academic and government markets.
Analysts pressed management on how Seer can offset the funding slowdown and whether biopharma can make up for weaker academic/government demand. Omid said biopharma spending is improving, the sales cycle has shortened to about 6 months from high single-digit months, and the company is focusing more on larger, funded accounts with recurring sample volume; he also said Seer expects to announce one 10,000-plus-sample customer in the coming weeks. On pull-through, Charles said consumable ordering was relatively flat sequentially and remains project-driven, but the company is getting longer visibility into customer pipelines and working to broaden repeat usage within accounts.
The bull case from this call is that Seer’s technology is gaining credibility through publications, large cohort studies, and AI-related applications, which management says are reducing the need for proof-of-concept work. Management also pointed to new large biopharma customers, sequential consumable purchases, and a long-term revenue model built on repeat sample processing and account expansion. The balance sheet remains strong, with about $198 million in cash and investments and management saying that is sufficient to reach cash flow break-even under the plan.
The main risk is that revenue conversion is still being slowed by academic/government funding constraints and longer purchasing timelines, leading to a material guide cut. Management also acknowledged that uncertainty from the activist campaign and acquisition proposals made some customers hesitate, and pull-through was only relatively flat sequentially. Gross margin is still well below the company’s long-term target, and management said quarterly margin will remain variable depending on the mix of instruments, consumables, and services.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.3%
- Shares Outstanding
- 55.81M
- Float Shares
- 40.36M
of shares held by institutions
59 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Softbank Group Corp. | 5.14M | 0 |
| Vanguard Group Inc | 2.19M | ▼ 33.99K |
| Bml Capital Management, LLC | 2.19M | ▲ 2.19M |
| Acadian Asset Management LLC | 1.95M | 0 |
| Vanguard Capital Management LLC | 1.78M | ▼ 46.41K |
| Blackrock, Inc. | 1.37M | ▼ 60.15K |
| Renaissance Technologies LLC | 987.60K | ▲ 2.10K |
| Aju Ib Investment Co., Ltd. | 816.38K | 0 |
| Nano Cap New Millennium Growth Fund L P | 700.00K | ▼ 125.00K |
| Citadel Advisors LLC | 519.31K | ▲ 519.31K |
| Two Sigma Investments, LP | 492.30K | ▼ 19.30K |
| Geode Capital Management, LLC | 491.13K | ▲ 30.70K |
Held by 44 ETFs
Biggest fund positions in SEER by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Endweiss Charles | sell | 2,447 |
| Nov 2, 26 | Endweiss Charles | other | 35,000 |
| Nov 2, 26 | Endweiss Charles | other | 65,000 |
| Oct 1, 26 | Endweiss Charles | other | 0 |
| Oct 1, 26 | Endweiss Charles | other | 0 |
| Oct 1, 26 | Endweiss Charles | other | 0 |
| Oct 1, 26 | Endweiss Charles | other | 0 |
| Oct 1, 26 | Endweiss Charles | other | 0 |
| Oct 1, 26 | Endweiss Charles | other | 0 |
| Oct 1, 26 | Endweiss Charles | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SEER coverage
Recent articles, reports, and earnings notes.
Want a deeper read on SEER?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Seer, Inc. (SEER) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Seer Q3 Earnings Call Highlights
marketbeat.com · Nov 10
Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance
globenewswire.com · Nov 10
Seer Secures Key Victory in ITC Patent Dispute as Investigative Staff Backs All Requested Remedies Against Nanomics
globenewswire.com · Nov 5
Radoff-JEC Group Issues Open Letter Condemning Seer's Unexplained and Seemingly Illogical Decision to Remain a Public Company
businesswire.com · Nov 2
Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process
globenewswire.com · Oct 29
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
gurufocus.com · Oct 25
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
gurufocus.com · Oct 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
